Free Trial

Elevance Health (ELV) Stock Price, News & Analysis

Elevance Health logo
$381.25 +8.07 (+2.16%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$380.70 -0.55 (-0.14%)
As of 07:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Elevance Health Stock (NYSE:ELV)

Key Stats

Today's Range
$372.90
$382.09
50-Day Range
$372.33
$429.08
52-Week Range
$357.45
$567.26
Volume
1.77 million shs
Average Volume
1.58 million shs
Market Capitalization
$86.14 billion
P/E Ratio
14.88
Dividend Yield
1.79%
Price Target
$498.87
Consensus Rating
Moderate Buy

Company Overview

Elevance Health, Inc. (NYSE: ELV) is a leading health benefits company in the United States, offering a wide range of medical, behavioral health, dental, vision and pharmacy solutions. Through its core health insurance business, the company provides individual, employer-sponsored and government-sponsored plans, including Medicare Advantage and Medicaid programs. Its Evernorth subsidiary delivers pharmacy care services, care coordination and digital health capabilities designed to improve clinical outcomes and lower costs for members and clients.

Founded in 1945 as a regional Blue Cross plan in Indianapolis, the company expanded through mergers and acquisitions over several decades, adopting the Anthem name in 2004. In June 2022, the organization rebranded as Elevance Health to emphasize its focus on elevating health outcomes and advancing whole-person care. This strategic shift reflects the company’s commitment to leveraging data analytics, digital tools and an integrated care model.

Elevance Health’s operations span all 50 states and the District of Columbia, serving over 50 million members across commercial, Medicare and Medicaid lines of business. The company partners with a network of more than one million physicians and health care professionals, as well as thousands of hospitals and other facilities. Its Evernorth segment collaborates with employers, health systems and pharmacy benefit managers to offer specialty drug management, site-of-care solutions and virtual care services.

Under the leadership of President and CEO Gail Boudreaux—who assumed the role in November 2020—the executive team continues to drive innovation in care delivery and member engagement. Elevance Health emphasizes social responsibility by investing in community health initiatives, addressing health disparities and supporting programs aimed at improving access to care for underserved populations.

AI Generated. May Contain Errors.

Elevance Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
98th Percentile Overall Score

ELV MarketRank™: 

Elevance Health scored higher than 98% of companies evaluated by MarketBeat, and ranked 29th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elevance Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Elevance Health has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Elevance Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Elevance Health are expected to grow by 14.99% in the coming year, from $33.96 to $39.05 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elevance Health is 14.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.09.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elevance Health is 14.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.25.

  • Price to Earnings Growth Ratio

    Elevance Health has a PEG Ratio of 0.97. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    Elevance Health has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Elevance Health's valuation and earnings.
  • Percentage of Shares Shorted

    1.11% of the float of Elevance Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevance Health has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elevance Health has recently increased by 13.64%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Elevance Health pays a meaningful dividend of 1.79%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Elevance Health has been increasing its dividend for 14 years.

  • Dividend Coverage

    The dividend payout ratio of Elevance Health is 26.69%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Elevance Health will have a dividend payout ratio of 17.52% next year. This indicates that Elevance Health will be able to sustain or increase its dividend.

  • Read more about Elevance Health's dividend.
  • Percentage of Shares Shorted

    1.11% of the float of Elevance Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevance Health has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elevance Health has recently increased by 13.64%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Elevance Health has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 60 news articles for Elevance Health this week, compared to 28 articles on an average week.
  • Search Interest

    Only 9 people have searched for ELV on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Elevance Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Elevance Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,949,074.00 in company stock.

  • Percentage Held by Insiders

    Only 0.29% of the stock of Elevance Health is held by insiders.

  • Percentage Held by Institutions

    89.24% of the stock of Elevance Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Elevance Health's insider trading history.
Receive ELV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevance Health and its competitors with MarketBeat's FREE daily newsletter.

ELV Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
ELV INVESTOR DEADLINE: Elevance Health, Inc. ...
See More Headlines

ELV Stock Analysis - Frequently Asked Questions

Elevance Health's stock was trading at $368.90 on January 1st, 2025. Since then, ELV shares have increased by 3.3% and is now trading at $381.25.
View the best growth stocks for 2025 here
.

Elevance Health, Inc. (NYSE:ELV) announced its quarterly earnings results on Tuesday, April, 22nd. The company reported $11.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.60 by $1.37. The company earned $48.77 billion during the quarter, compared to analysts' expectations of $46.26 billion. Elevance Health had a net margin of 3.23% and a trailing twelve-month return on equity of 18.61%.
Read the conference call transcript
.

Elevance Health subsidiaries include these companies: Beacon Health Options, Aspire Healthcare Corp, America’s 1st Choice, HealthSun Health Plans, Simply Healthcare Holdings, Amerigroup, 1-800 Contacts, and more.

Shares of ELV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevance Health investors own include NVIDIA (NVDA), Chevron (CVX), Meta Platforms (META), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY), Netflix (NFLX) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
4/22/2025
Record date for 6/25 Dividend
6/10/2025
Ex-Dividend for 6/25 Dividend
6/10/2025
Dividend Payable
6/25/2025
Today
6/29/2025
Next Earnings (Estimated)
7/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Medical Services
Sub-Industry
Managed Health Care
Current Symbol
NYSE:ELV
Employees
104,200
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$498.87
High Stock Price Target
$555.00
Low Stock Price Target
$440.00
Potential Upside/Downside
+30.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
16 Analysts

Profitability

Trailing P/E Ratio
14.88
Forward P/E Ratio
11.23
P/E Growth
0.97
Net Income
$5.98 billion
Pretax Margin
4.23%

Debt

Sales & Book Value

Annual Sales
$177.01 billion
Cash Flow
$39.14 per share
Price / Cash Flow
9.74
Book Value
$178.62 per share
Price / Book
2.13

Miscellaneous

Free Float
225,280,000
Market Cap
$86.14 billion
Optionable
Optionable
Beta
0.60

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NYSE:ELV) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners